INSIGHTS ON DRUG DEVELOPMENT

• Rapidly Assess Drug Response In 2D And 3D Breast Cancer Model Systems

  For years, 2D cell cultures have been crucial in drug discovery. Explore how 3D cultures offer more biologically relevant models today that enhance cancer research and drug efficacy assessments.

• ADC Development Grows More Complex — SPR Insights Bring Clarity

  Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.

• AI Based Screening And Selection Of Co-Formers For Co-Crystallization

  Explore how AI and quantum chemistry are accelerating co-crystal screening and solving solubility challenges in drug development, as well as key technical considerations for identifying optimal co-formers.

• Imagine The Future: An Enhanced Oligonucleotide Synthesis Process

  Gain practical guidance for improving oligo quality, see how an advanced synthesis platform supports production, and explore a software interface designed to make daily operations more intuitive.

• Denaturing SEC-MS Analysis Of High Molecular Weight Impurities

  3/18/2026

  Look at how denaturing SEC‑MS uncovers low‑level oligomers and truncated variants in GLP‑1 peptides, offering clarity on impurity profiles and supporting confident assessment of molecular integrity.

• Design Scalable Downstream Processes With Practical Strategies

  5/11/2026

  Downstream purification is becoming more complex as new modalities enter development. Learn how advanced analytics and chromatography strategies can support scalable, confident process development.

• A Simple Method For Cell Growth Media Preparation

  11/3/2025

  Explore how powder media and sterile fluid handling can reduce contamination risk and improve efficiency in viral vector production, especially for HEK293-based AAV workflows.

• Delivering Critical Therapies With Speed And Safety

  6/26/2026

  Faster approvals depend on treating regulation as part of development, not the finish line. See how early quality planning and strong agency communication can move therapies toward patients sooner.

• Alzheimer's Disease Pathway

  3/24/2025

  Alzheimer’s disease (AD) affects 50 million people globally, causing cognitive decline. Explore the signaling pathways of amyloid beta and tau proteins, linking them to neuronal death and AD symptoms.